Rash Signals Better Outcome for Erlotinib Therapy in NSCLC

Ben Leach
Published: Wednesday, Sep 05, 2012
Dr. Roman Perez-Soler

Román Pérez-Soler, MD
Professor of Medicine, Chief, Division of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

Cutaneous rash is a common adverse event among patients with non-small cell lung cancer (NSCLC) who receive erlotinib, but if it develops early on in the treatment course, it could be an indication that the patient will experience a significantly greater survival benefit.

That correlation emerged from a retrospective analysis of patients who took erlotinib in a study launched more than a decade ago.

Erlotinib inhibits the tyrosine kinase associated with epidermal growth factor receptor (EGFR), and the new data build upon the knowledge of how agents in this class of inhibitors affect patients, said Román Pérez-Soler, MD, lead author of the study, which was presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago in June.1

“We know that all the EGFR inhibitors produce this side effect, and now we have more and more of these agents being developed for a wide variety of diseases,” said Pérez-Soler. “It was very intriguing to observe that individuals that presented with severe rash tended to live longer. This triggered a lot of discussion whether there was a real correlation between the two.”

The study presented at ASCO was a subanalysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, the pivotal phase III trial that began in 2001 and led to the FDA approval three years later of erlotinib for the treatment of locally advanced or metastatic NSCLC under the brand name Tarceva (Genentech/Astellas).

The BR.21 study enrolled 731 patients with stage IIIB or stage IV NSCLC who had failed first- or second-line chemotherapy. Those patients were randomized in a 2:1 ratio to treatment with either erlotinib (n = 488) or a placebo (n = 243). However, three patients in the erlotinib arm and one patient in the placebo arm did not receive any study drug.

In the subanalysis, Pérez-Soler and colleagues found that 366 of the patients who received erlotinib (75%) developed a rash at any point in time during treatment, while 40 patients in the placebo group developed a rash (17%).

Among patients treated with erlotinib, 75% of rash episodes occurred within the first two weeks of treatment, and 95% were reported within 10 weeks. The incidence of rashes varied depending on the grade, with grade 1 and 2 rashes peaking by the third week of treatment and grade 3 rashes peaking at the fifth week.

Table. Median OS by Rash Status
in Patients on Erlotinib1

Rash Grade Rash Group
No Rash Group
Any grade 37.4 wks (311) 11.1 wks (65)
Grade ≥2 40.4 wks (193)
Grade 1 30.2 wks (118)

OS indicates overall survival.

Rash Group was defined as patients presenting with cutaneous rash by week 10 of erlotinib therapy. No Rash Group consists of 55 patients who did not present with any rash and 10 patients who presented with skin toxicity after week 10.

The researchers used the 10- week mark to analyze the impact of skin toxicity; patients who developed a rash by week 10 were placed in the “rash group,” while those who either did not experience any rash or presented with a rash after week 10 were placed in the “no rash” group (Table).

In all, 311 patients developed a rash by week 10 of erlotinib therapy. The median overall survival (OS) of patients in the “rash” group was 37.4 weeks. For the 65 patients in the “no rash” group, median OS was 11.1 weeks (HR = 0.51; 95% CI, 0.38-0.68; P < .0001).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication